• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to Boyd et al., "Evidence that remdesivir treatment reduces viral titers in patients with COVID-19".

作者信息

Faghihi Isa, Yan Victoria C

机构信息

University of Texas Southwestern Medical Center, Dallas, Texas, USA.

出版信息

Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0136324. doi: 10.1128/aac.01363-24. Epub 2024 Nov 7.

DOI:10.1128/aac.01363-24
PMID:39508590
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11619388/
Abstract
摘要

相似文献

1
Reply to Boyd et al., "Evidence that remdesivir treatment reduces viral titers in patients with COVID-19".对博伊德等人《瑞德西韦治疗可降低COVID-19患者病毒载量的证据》一文的回复
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0136324. doi: 10.1128/aac.01363-24. Epub 2024 Nov 7.
2
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19.瑞德西韦治疗可降低COVID-19患者病毒载量的证据。
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0126624. doi: 10.1128/aac.01266-24. Epub 2024 Nov 7.
3
Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.洛匹那韦利托那韦和瑞德西韦的 COVID-19 临床试验中的统计问题及经验教训。
JMIR Public Health Surveill. 2020 Jul 10;6(3):e19538. doi: 10.2196/19538.
4
Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: A retrospective case-control study.瑞德西韦显著降低 COVID-19 住院患者鼻咽拭子中 SARS-CoV-2 病毒载量：一项回顾性病例对照研究。
J Med Virol. 2022 May;94(5):2284-2289. doi: 10.1002/jmv.27598. Epub 2022 Jan 28.
5
SARS-CoV-2 viral load dynamics in immunocompromised critically ill patients on remdesivir treatment.接受瑞德西韦治疗的免疫功能低下重症患者中SARS-CoV-2病毒载量动态变化
Multidiscip Respir Med. 2022 May 10;17:825. doi: 10.4081/mrm.2022.825. eCollection 2022 Jan 12.
6
Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19.洛匹那韦/利托那韦与瑞德西韦在降低COVID-19患者病毒载量及病毒脱落持续时间方面的疗效相当。
Microorganisms. 2024 Aug 16;12(8):1696. doi: 10.3390/microorganisms12081696.
7
Remdesivir and its antiviral activity against COVID-19: A systematic review.瑞德西韦及其对新型冠状病毒肺炎的抗病毒活性：一项系统评价。
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:123-127. doi: 10.1016/j.cegh.2020.07.011. Epub 2020 Aug 7.
8
The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids.瑞德西韦与 COVID-19 患者接受类固醇治疗的院内结局的相关性。
J Antimicrob Chemother. 2021 Sep 15;76(10):2690-2696. doi: 10.1093/jac/dkab256.
9
A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.在以色列一家大型三级中心住院的 COVID-19 患者中评估瑞德西韦对病毒载量影响的真实环境评估。
Clin Microbiol Infect. 2021 Jun;27(6):917.e1-917.e4. doi: 10.1016/j.cmi.2021.02.029. Epub 2021 Mar 9.
10
Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19.瑞德西韦对 COVID-19 住院患者病毒血症患者体内 SARS-CoV-2 病毒动力学和死亡率的影响。
J Antimicrob Chemother. 2023 Nov 6;78(11):2735-2742. doi: 10.1093/jac/dkad295.

本文引用的文献

1
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19.瑞德西韦治疗可降低COVID-19患者病毒载量的证据。
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0126624. doi: 10.1128/aac.01266-24. Epub 2024 Nov 7.
2
Remdesivir treatment does not reduce viral titers in patients with COVID-19.瑞德西韦治疗不能降低 COVID-19 患者的病毒滴度。
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0085624. doi: 10.1128/aac.00856-24. Epub 2024 Jul 18.
3
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV).瑞德西韦治疗新型冠状病毒肺炎的临床疗效：一项开放标签、随机对照的自适应平台试验（PLATCOV）。
J Infect Dis. 2023 Nov 11;228(10):1318-1325. doi: 10.1093/infdis/jiad275.
4
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.瑞德西韦和其他三种药物治疗 COVID-19 住院患者：世卫组织团结随机试验的最终结果和更新的荟萃分析。
Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2.
5
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.在年轻成年人中进行 SARS-CoV-2 人体挑战的安全性、耐受性和病毒动力学。
Nat Med. 2022 May;28(5):1031-1041. doi: 10.1038/s41591-022-01780-9. Epub 2022 Mar 31.
6
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.